Chiara Bennati
A5052032389- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Cancer Genomics and Diagnostics
- Lung Cancer Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Cancer-related Molecular Pathways
- Advanced Breast Cancer Therapies
- PI3K/AKT/mTOR signaling in cancer
- Cancer therapeutics and mechanisms
- Neuroendocrine Tumor Research Advances
- Cholangiocarcinoma and Gallbladder Cancer Studies
- HER2/EGFR in Cancer Research
- Ferroptosis and cancer prognosis
- Pancreatic and Hepatic Oncology Research
- Economic and Financial Impacts of Cancer
- RNA modifications and cancer
- COVID-19 and healthcare impacts
- Cancer survivorship and care
- Gastric Cancer Management and Outcomes
- Inflammatory Biomarkers in Disease Prognosis
- Genetic factors in colorectal cancer
- Lymphoma Diagnosis and Treatment
- Global Cancer Incidence and Screening
Ospedale Santa Maria
2012-2025
Ospedale "Santa Maria delle Croci" di Ravenna
2018-2025
Azienda Unità Sanitaria Locale Della Romagna
2017-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2025
Medica (Italy)
2023
GTx (United States)
2018
Azienda Ospedaliera di Perugia
2012-2017
Weatherford College
2015
Azienda Ospedaliera S.Maria
2011
Abstract Purpose: To analyze the impact of TP53 mutations on response to first-line tyrosine kinase inhibitors (TKI) in patients with EGFR-mutated non–small cell lung cancer (NSCLC). Experimental Design: 136 NSCLC receiving TKIs were analyzed. evaluated 123 relation disease control rate (DCR), objective (ORR), progression-free survival (PFS), and overall (OS). Results: observed 37 (30.1%), 10 (27.0%), 6 (16.2%), 9 (24.3%), 12 (32.4%) exons 5, 6, 7, 8, respectively. DCR was 70% TP53-mutated...
COVID-19 has disrupted the global health care system since March 2020. Lung cancer (LC) patients (pts) represent a vulnerable population highly affected by pandemic. This multicenter Italian study aimed to evaluate whether outbreak had an impact on access diagnosis and treatment of LC pts compared with pre-pandemic time.Consecutive newly diagnosed referred 25 Oncology Departments between December 2020 were included. Access rate temporal intervals date symptoms onset diagnostic therapeutic...
Background Pembrolizumab monotherapy is an established front-line treatment for advanced non-small cell lung cancer (NSCLC) with programmed death-ligand 1 (PD-L1) tumor proportion score (TPS)≥50%. However, real-world data on its long-term efficacy remains sparse. Methods This study assessed 5-year outcomes of first-line pembrolizumab in a large, multicenter, cohort patients NSCLC and PD-L1 TPS≥50%, referred to as Pembro-real 5Y. Individual patient-level (IPD) from the experimental arm...
Extensive stage Small-Cell Lung Cancer (ES-SCLC) is the most lethal lung cancer, and addition of immunotherapy conferred a slight survival benefit for patients. molecular profiling patients treated with chemotherapy (CT) or plus (CT+IO) would be able to identify factors associated patients' survival. In this retrospective study, 99 ES-SCLC were considered. Of 79 includible patients, 42 received CT (median age 71 y/o, I-IIIQ: 65-76), 37 CT+IO I-IIIQ 66-75). The FoundationOne CDx assay was...
This study aimed at investigating feasibility of programmed death ligand-1 (PD-L1) testing in plasma samples advanced NSCLC patients receiving first-line treatment, assessing whether circulating (c)PD-L1 levels were modified by the therapy and baseline cPD-L1 associated with patients' clinical responses survival outcome.Peripheral blood collected from 16 healthy volunteers 56 newly diagnosed before 12th week during course therapy. The level PD-L1 was measured using human (PD-L1/CD274) ELISA...
•Largest dataset of NSCLC with uncommon EGFR alterations treated osimertinib.•Best outcomes compound uncommon–common mutations and G719X, L861X, or S768I.•Heterogeneous activity rarer mutations; no response at E709 residue.•Confirmed in the central nervous system, intracranial ORR 58%.•Amplification MET, TP53 mutations, E709K are putative mechanisms resistance. BackgroundOsimertinib represents standard care for treatment advanced non-small-cell lung cancer (NSCLC) harboring classical...
Introduction: Central nervous system (CNS) metastases represent an important cause of morbidity and mortality in non-small cell lung cancer (NSCLC) patients. Local approaches neurosurgery (usually for single brain lesions), whole radiotherapy, stereotactic radiosurgery are often withheld the treatment NSCLC-derived (BMs). However, systemic is consistently emerging as option patients with asymptomatic BMs, which could allow delaying cranial radiotherapy at symptomatic/radiological...
Hyponatremia in cancer patients is often caused by the syndrome of inappropriate antidiuretic hormone secretion (SIADH). The aim this observational multicenter study was to analyze medical and economic implications SIADH setting. This included 90 oncological from 28 Italian institutions that developed between January 2010 September 2015. Data on clinical-pathological characteristics, anticancer therapies, hyponatremia, related treatments were statistically analyzed. majority lung (73%) with...
The prevalence of Skeletal Related Adverse Events (SREs) in EGFR mutated non-small cell lung cancer (NSCLC) patients with bone metastases, treated modern tyrosine kinase inhibitors (TKIs), has been scarcely investigated.We retrospectively evaluated the data NSCLC metastases TKIs 12 Italian centers from 2014 to 2019, primary aim explore type and frequency SREs.Seventy-seven out 274 enrolled (28%) developed at least one major SRE: 55/274 (20%) fractures, 30/274 (11%) spinal cord compression,...
Abstract Background Real-life spectrum and survival implications of immune-related adverse events (irAEs) in patients treated with extended interval dosing (ED) immune checkpoint inhibitors (ICIs) are unknown. Methods Characteristics 812 consecutive solid cancer who received at least 1 cycle ED monotherapy (pembrolizumab 400 mg Q6W or nivolumab 480 Q4W) after switching from canonical (CD; pembrolizumab 200 Q3W 240 Q2W) upfront were retrieved. The primary objective was to compare irAEs...
// Manolo D'Arcangelo 1 , Armida D'Incecco 2 Claudia Ligorio 3 Stefania Damiani Maurizio Puccetti 4 Sara Bravaccini 5 Luigi Terracciano 6 Chiara Bennati Gabriele Minuti Silvia Vecchiarelli Lorenza Landi Marina Milesi 7 Alberto Meroni 8 Ravaioli Maria Maddalena Tumedei Matteo Incarbone and Federico Cappuzzo AUSL della Romagna, Department of Oncology-Hematology, Ravenna, Italy University Hospital Siena, Medical Oncology Immunotherapy, Center for Immuno-Oncology, Bologna, DIMES, Pathology,...